Objective: A randomized, double-blind, placebo-controlled clinical trial was performed to assess the effect of omega-3 supplementation (3 g/day) on atherosclerosis progression by measuring carotid intima-media thickness (cIMT) in hemodialysis (HD) patients.
Methods: A total of 54 HD patients were randomized into two groups: Intervention group ( = 27), in which patients were given 3 g/day omega-3 for 6 months and placebo group ( = 27), in which patients received placebo using the same administration protocol. All patients underwent a carotid artery ultrasound scan to measure cIMT at baseline and at 6 months.
Findings: cIMT decreased significantly in omega-3 group (0.79 ± 0.21 mm at baseline vs. 0.65 ± 0.18 mm at 6 months, < 0.001). On the other hand, a nonsignificant increase in cIMT was seen in placebo group (0.75 ± 0.17 mm at baseline vs. 0.79 ± 0.17 mm at 6 months, = 0.12). Moreover, cIMT was statistically significantly different between omega-3 and placebo groups at 6 months ( < 0.001). After 6 months, a statistically significant increase was observed in high-density lipoprotein level in omega-3 group compared to placebo group ( = 0.03). Urea reduction ratio was also statistically significantly higher in omega-3 than placebo group at 6 months ( = 0.03). No significant difference was observed in terms of other variables between the two groups.
Conclusion: These data suggested that omega-3 supplementation plays a protective role in the progression of atherosclerosis in HD patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084482 | PMC |
| http://dx.doi.org/10.4103/2279-042X.192451 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
'Which treatment do you believe you received?' A randomised blinding feasibility trial of spinal manual therapy.
Chiropr Man Therap
January 2025
Musculoskeletal Epidemiology Research Group, University of Zurich and Balgrist University Hospital, Zurich, Switzerland.
Background: Blinding is essential for mitigating biases in trials of low back pain (LBP). Our main objectives were to assess the feasibility of blinding: (1) participants randomly allocated to active or placebo spinal manual therapy (SMT), and (2) outcome assessors. We also explored blinding by levels of SMT lifetime experience and recent LBP, and factors contributing to beliefs about the assigned intervention.
View Article and Find Full Text PDFEffects of bright light therapy on cingulate cortex dynamic functional connectivity and neurotransmitter activity in young adults with subthreshold depression.
J Affect Disord
January 2025
Medical Imaging Center, First Affiliated Hospital of Jinan University, Guangzhou 510630, China; Institute of Molecular and Functional Imaging, Jinan University, Guangzhou 510630, China. Electronic address:
Background: The neurobiological mechanisms behind the antidepressant effect of bright light therapy (BLT) are unclear. We aimed to explore the dynamic functional connectivity (dFC) changes of the cingulate cortex (CC) in subthreshold depression (StD).
Methods: The StD participants (38 BLT and 39 placebo) underwent resting-state functional magnetic resonance imaging (rs-fMRI) and mood assessment before and after eight-week BLT.
A Single Night in Hypoxia Either with or without Ketone Ester Ingestion Reduces Sleep Quality Without Impacting Next Day Exercise Performance.
Med Sci Sports Exerc
November 2024
Exercise Physiology Research Group, Department of Movement Sciences, KU Leuven, Leuven, BELGIUM.
Background: Sleeping at altitude is highly common in athletes as an integral part of altitude training camps or sport competitions. However, concerns have been raised due to expected negative effects on sleep quality, thereby potentially hampering exercise recovery and next-day exercise performance. We recently showed that ketone ester (KE) ingestion beneficially impacted sleep following strenuous, late evening exercise in normoxia, and alleviated hypoxemia.
View Article and Find Full Text PDFEffect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy.
Maturitas
November 2024
Hormone Hamburg, Hamburg, Germany. Electronic address:
Objective: To report patient-reported quality-of-life (QOL) outcomes in the DAYLIGHT study.
Study Design: DAYLIGHT was a phase 3b, randomized, double-blind, 24-week, placebo-controlled study. Participants were women aged ≥40 to ≤65 years with moderate to severe vasomotor symptoms (VMS) considered unsuitable for hormone therapy (HT) (contraindications, caution, stoppers, or averse) randomized 1:1 to placebo or fezolinetant 45 mg once daily.
Does curcumin supplementation affect inflammation, blood count and serum brain-derived neurotropic factor concentration in amateur long-distance runners?
PLoS One
January 2025
Institute of Sport Sciences, Jerzy Kukuczka Academy of Physical Education in Katowice, Katowice, Poland.
Curcumin is known for its potential health benefits; however, the evidence remains inconclusive regarding its necessity as a supplement for athletes during the preparatory phase of training. This study aimed to assess the effect of 6-week curcumin supplementation at a dose of 2g/day on selected inflammatory markers, blood count, and brain-derived neurotropic factor (BDNF) levels in middle-aged amateur long-distance runners during the preparatory period of a macrocycle. Thirty runners were randomly assigned to either a curcumin-supplemented group (CUR, n = 15) or a placebo group (PLA, n = 15).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!